The U.S. Food and Drug Administration’s Orthopedic and Rehabilitation Devices Advisory Committee has recommended a Genzyme Corp. osteoarthritis pain reliever for approval.
Genzyme, which has significant operations in Central Massachusetts, is seeking FDA approval for Synvisc-One, which is a one-dose alternative to its Synvisc. The company expects the FDA to take formal action on its pre-market approval application by Dec. 23.
Synvisc is an injected treatment for osteoarthritis of the knee. Synvisc-One has already been approved for use in the European Union and in several Asian and Latin American countries.
